Adipocytes Metabolize, Inactivate Daunorubicin
THURSDAY, Nov. 9, 2017 -- Adipocytes metabolize and inactivate the anthracycline daunorubicin, according to a study published online Nov. 8 in Molecular Cancer Research.
Xia Sheng, Ph.D., from Children's Hospital Los Angeles, and colleagues examined whether adipocytes clear daunorubicin from the tumor microenvironment. Fluorescence was used to evaluate intracellular daunorubicin concentrations. Expression of the daunorubicin-metabolizing enzymes aldo-keto reductases (AKR) and carbonyl reductases (CBR) was measured by quantitative polymerase chain reaction and immunoblot.
The researchers found that adipocytes absorbed and metabolized daunorubicin to daunorubicinol, which reduced its anti-leukemia effect. Daunorubicin conversion to daunorubicinol was confirmed in vivo in murine studies. High levels of AKR and CBR isoenzymes, which deactivate anthracyclines, were expressed by adipocytes. Adipocyte protein levels of AKR1C1, AKR1C2, and AKR1C3 were higher than all other human noncancerous cell types.
"These results could be clinically important for adipocyte-rich cancer microenvironments such as omentum, breast, and marrow," the authors write. "As AKR and CBR enzymes metabolize several drugs, and can be expressed at higher levels in obese individuals, this proof-of-principle finding has important implications across many diseases."
© 2020 HealthDay. All rights reserved.
Posted: November 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.